Trials
Search / Trial NCT06445673

A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients

Launched by AOP ORPHAN PHARMACEUTICALS AG · Jun 4, 2024

Trial Information

Current as of February 18, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Patients previously participating in the randomized TripleTRE trial who are able and willing to provide a signed informed consent for study participation in NIS
  • Exclusion Criteria:
  • 1. Lost to follow-up patients of TripleTRE study
  • 2. Patients who discontinued all medicinal PAH treatments (e.g. after successful lung transplantation)
  • 3. Patients who withdrew from the initial TripleTRE trial due to significant non-compliance with trial requirements (not adhering to therapy, not coming to hospital visits)

About Aop Orphan Pharmaceuticals Ag

AOP Orphan Pharmaceuticals AG is a specialized biopharmaceutical company focused on developing innovative therapies for rare and complex diseases. With a commitment to addressing unmet medical needs, the company engages in the research, development, and commercialization of orphan drugs that aim to improve the quality of life for patients with debilitating conditions. AOP Orphan leverages its expertise in various therapeutic areas, including hematology, oncology, and neurology, to advance its clinical programs and collaborate with healthcare professionals and institutions worldwide. Driven by a patient-centric approach, AOP Orphan Pharmaceuticals AG strives to deliver transformative solutions that enhance treatment options for underserved populations.

Locations

Szeged, , Hungary

Madrid, , Spain

Barcelona, , Spain

Vienna, , Austria

Vienna, , Austria

Greifswald, , Germany

Strasbourg, , France

Praha, , Czechia

Rome, , Italy

Olomouc, , Czechia

Berlin, , Germany

Linz, , Austria

Paris, , France

Dresden, , Germany

Budapest, , Hungary

Kraków, , Poland

Otwock, , Poland

Bucharest, , Romania

Târgu Mureş, , Romania

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0